Vera Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Vera Therapeutics, Inc. (VERA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $14.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- Vera Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $9.43M.
- Vera Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $5.14M, a 12.47% decline year-over-year.
- Vera Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $372.00K.
- Vera Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$606.00K, a 132.88% decline year-over-year.
- Vera Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $3.93M.
- Vera Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$981.00K.
- Vera Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$173.00K, a 102.11% decline from fiscal 2022.
- Vera Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $8.18M, a 254.81% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $14.57M 10-Q · filed 2026-08-10 | $14.94M derived: sum of 3 quarters · filed 2026-08-10 | $14.34M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $5.14M 10-Q · filed 2026-05-07 | $5.51M derived: sum of 2 quarters · filed 2026-05-07 | $4.91M derived: sum of 3 quarters · filed 2026-05-07 | $3.19M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$234.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.95M derived: sum of 3 quarters · filed 2026-08-10 | $3.93M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$606.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$2.32M derived: sum of 2 quarters · filed 2026-08-10 | $3.56M 10-Q · filed 2025-11-05 | $3.06M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.16M 10-Q · filed 2026-08-10 | $3.67M derived: sum of 3 quarters · filed 2026-08-10 | $5.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $5.88M 10-Q · filed 2026-05-07 | $5.38M derived: sum of 2 quarters · filed 2026-05-07 | $7.22M derived: sum of 3 quarters · filed 2026-05-07 | $4.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$496.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.35M derived: sum of 2 quarters · filed 2026-02-26 | -$1.37M derived: sum of 3 quarters · filed 2026-02-26 | -$981.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$877.00K derived: sum of 2 quarters · filed 2025-11-05 | -$485.00K 10-Q · filed 2025-11-05 | -$1.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.33M 10-Q · filed 2025-08-05 | -$3.14M derived: sum of 3 quarters · filed 2026-02-26 | -$1.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $392.00K 10-Q · filed 2025-05-07 | -$417.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.67M derived: sum of 3 quarters · filed 2026-02-26 | $3.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$809.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.28M derived: sum of 2 quarters · filed 2026-02-26 | $3.58M derived: sum of 3 quarters · filed 2026-02-26 | -$173.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.38M derived: sum of 2 quarters · filed 2024-11-07 | $636.00K 10-Q · filed 2024-11-07 | $1.12M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.45M 10-Q · filed 2024-08-08 | -$969.00K derived: sum of 3 quarters · filed 2024-08-08 | -$815.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$3.75M 10-Q · filed 2024-05-10 | -$3.27M derived: sum of 2 quarters · filed 2024-05-10 | -$3.11M derived: sum of 3 quarters · filed 2024-05-10 | $491.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $636.00K derived: sum of 2 quarters · filed 2024-03-27 | $4.24M derived: sum of 3 quarters · filed 2024-03-27 | $8.18M 10-K · filed 2024-03-27 |
| 2022-09-30 | $154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.76M derived: sum of 2 quarters · filed 2023-11-09 | $7.70M 10-Q · filed 2023-11-09 | $6.99M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $7.55M 10-Q · filed 2023-08-10 | $6.84M derived: sum of 3 quarters · filed 2023-08-10 | $6.21M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.94M 10-Q · filed 2023-05-11 | $3.24M derived: sum of 2 quarters · filed 2023-05-11 | $2.60M derived: sum of 3 quarters · filed 2023-05-11 | $6.12M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$706.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$1.34M derived: sum of 2 quarters · filed 2023-03-28 | $2.18M derived: sum of 3 quarters · filed 2023-03-28 | $2.31M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$632.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.88M derived: sum of 2 quarters · filed 2022-11-09 | $3.01M 10-Q · filed 2022-11-09 | $3.14M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $3.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $3.64M 10-Q · filed 2022-08-10 | $3.77M derived: sum of 3 quarters · filed 2022-08-10 | $3.63M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $127.00K 10-Q · filed 2022-05-16 | $256.00K derived: sum of 2 quarters · filed 2022-05-16 | $114.00K derived: sum of 3 quarters · filed 2022-05-16 | $150.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$13.00K derived: sum of 2 quarters · filed 2022-03-28 | $23.00K derived: sum of 3 quarters · filed 2022-03-28 | $135.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | -$142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$106.00K derived: sum of 2 quarters · filed 2021-11-10 | $6.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $148.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $112.00K 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |